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Serum NCAM levels and cognitive deficits in first episode schizophrenia patients 
versus health controls 
Abstract 
Background: Neural cell adhesion molecule (NCAM) is a glycoprotein and plays an important role in cell-
cell adhesion, neural migration, neurite outgrowth, synaptic plasticity and brain development. We 
investigated the relationship between the serum NCAM concentration and cognitive deficit in first episode 
drug naïve schizophrenia (FES) patients. 
Methods: Thirty FES patients and thirty healthy controls were recruited for this study. Psychiatric 
symptoms were assessed by the positive and negative syndrome scale (PANSS). Cognitive functions 
were assessed by measurement and treatment research to improve cognition in schizophrenia 
(MATRICS) and consensus cognitive battery (MCCB). Serum levels of NCAM were determined by ELISA. 
Results: Schizophrenia patients had decreased serum NCAM concentrations than controls (−30%, p 
Conclusions: There were a close relationship between the serum NCAM concentrations and cognitive 
deficits in FES patients. Since NCAM has an important role in neurodevelopmental processes, these 
results support the neurodevelopmental dysfunction hypothesis of schizophrenia and suggest that an 
altered NCAM may be one of the risk factors for schizophrenia including cognitive deficits. 
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Neural cell adhesion molecule (NCAM), also called CD56, is a member of the 
immunoglobulin superfamily. It is expressed in both neurons and glial cells 
(Jorgensen and Bock, 1974). NCAM plays important roles in cell-cell adhesion, 
neural migration, neurite outgrowth, synaptic plasticity and brain development and is 
also involved in the processes of learning and memory formation (Kiryushko et al., 
2004; Kiss and Muller, 2001; Ronn et al., 1998). Previous studies have suggested a 
close relationship between the dysregulation of NCAM system and schizophrenia 
(Poltorak et al., 1995; Zhang et al., 2014). Animal studies have found that mice 
lacking NCAM have impaired spatial learning and sensorimotor gating (Wood et al., 
1998) and have disrupted long-term potentiation (Senkov et al., 2006). Furthermore, 
genetic association studies have identified NCAM as a candidate susceptibility gene 
for schizophrenia and its single nucleotide polymorphisms (SNPs) are associated with 
cognition deficits (Lewis et al., 2003; Sullivan et al., 2007). However, no study has 
investigated the relationship between the serum NCAM levels and cognitive deficits 
in first episode schizophrenia (FES) patients. Thus, the aim of this study was to 
investigate whether or not there are differences in serum NCAM levels between the 
FES patients and health controls, and the correlation between serum NCAM levels 
and cognitive function in FES patients. 
The research was carried out after Beijing Huilongguan Hospital Institutional Review 
Board approval and written informed consent. Thirty FES patients were recruited and 
the diagnoses were made and confirmed based on the Structured Clinical Interview 
for DSM-IV (SCID). Thirty healthy control (HC) subjects were recruited through 
advertisements via the local community. Psychiatric symptoms were assessed by the 
positive and negative syndrome scale (PANSS). Cognitive function was assessed by 
measurement and treatment research to improve cognition in schizophrenia 
(MATRICS) and consensus cognitive battery (MCCB). Serum levels of NCAM were 
measured by ELISA kit following the manufacturer’s instruction (RayBiotech, Inc. 
Norcross). The sensitivity for NCAM measurement was 0.5pg/ml, with intra-assay 
coefficients from 3% to 6%. All the samples were assayed in triplicate. 
 
There were no significant differences in age and gender distributions between FES 
and HC. HC had higher education than FES patients. There was a significantly 
positive correlation between the education and serum NCAM levels (r=0.362, 
p=0.005) considering all subjects. 
 
Figure 1 shows that the serum NCAM levels were 30% lower in FES patients 
compared with HC subjects (38.22±12.99 µg/ml vs 54.82±17.03 µg/ml, p<0.001). 
Cognitive scores on MCCB were significantly lower in FES patients than healthy 
controls (87.00±10.58 vs 56.67±12.60, p<0.001). The serum NCAM levels were 
positively correlated with the total scores of MCCB (r=0.438, p=0.003). Multiple 
regression analysis confirmed that serum NCAM level was an independent 
contributor to MCCB total Scores. 
 
The primary findings of this study were that NCAM levels were significantly lower in 
FES patients than healthy controls, and the decreased serum NCAM levels had a 
positive correlation with impaired cognitive function, which was an independent 
contributor to MCCB total Scores. However, several limitations of the study should 
be noted here. First, we measured NCAM in serum, but not in the cerebral spinal fluid 
or brain tissues. It was still uncertain whether peripheral NCAM levels can reflect 
similar changes in the central nervous system. The second was the relatively small 
sample size in each group. The correlation analyses were performed based on the 
combined group, future studies should verify these results in lager amount of sample.  
Third, the results showed that serum NCAM levels were significantly reduced in drug 
naïve first-episode patients. However, the effect of antipsychotic drug on NCAM 
expression still unknown. So, a longitudinal study may be required to examine the 
levels of NCAM of these FES patients following antipsychotic treatments.  
 
In conclusion, our results demonstrated that FES patients had significantly lower 
levels of serum NCAM concentration, which were correlated with cognitive deficits. 
Since NCAM has an important role in neurodevelopmental processes, these results 
support the neurodevelopmental dysfunction hypothesis of schizophrenia and suggest 
that altered NCAM may be one of the biomarkers for schizophrenia, especially for 
cognitive impairment. 
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